Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPAS pneumococcal vaccine efficacy study in infants
2011-002076-16Phase 3
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 10-valent pneumococcal conjugate vaccine in pneumococcal disease, community-acquired pneumonia (CAP) and acute otitis media (AOM) (2 arms), sponsored by GSK. Primary endpoint: Occurrence of likely bacterial community-acquired pneumonia.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal diseasecommunity-acquired pneumonia (CAP)acute otitis media (AOM)
Beyond the preview
Go deeper on 2011-002076-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002076-16.